Kim Cocks

8PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersCross-sectional analysisSocial program evaluationCancer therapy (excl. chemotherapy and radiation therapy)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 02, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial.

Horst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall

|Dec 18, 2024
Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: targeted literature review and best practice recommendations.

Kim Cocks, Bellinda L King-Kallimanis, Joel Sims

|May 16, 2023
Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.

K Forde, K Cocks, J R Wells

|Jul 09, 2022
How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales.

Kim Cocks, Jacqueline Buchanan

|Jan 15, 2022
Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients.

Pip Griffiths, John Devin Peipert, Andrea Leith

|Aug 25, 2019
Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.

Kate Sully, Andrew Trigg, Nicola Bonner

Pageof 2

Frequent Collaborators

1 joint publications

C Kyriakou

1 joint publications

Shaji Kumar

1 joint publications

Andrew Trigg

1 joint publications

Nicola Bonner